MiNK Therapeutics ( (INKT) ) has issued an announcement.
MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Board, with a term lasting until 2026. Dr. Kadlec’s role includes serving on the Corporate Governance and Nominating Committee, and he has been granted options to purchase shares of MiNK’s stock, vesting over three years. His compensation package includes both cash and equity, aligning with MiNK’s non-employee director program, and his appointment was formally announced via a press release.
For an in-depth examination of INKT stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
